Journal rankings · indicator year 2010
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2010
Pharmacology, Toxicology and Pharmaceutics journal rankings 2010
44 ranked journals · Field in Life Sciences
Pharmacology, Toxicology and Pharmaceutics has 44 ranked journals in 2010. The median journal has an OJR of 0.95, below the world average of 1.00, down 0.02 on 2009; Q1 starts at OJR 1.68. The top three are Current Drug Metabolism, Expert Opinion on Drug Delivery, and Pharmaceutical Research.
Ranks and citation indicators: 2010. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2007–2009, the window the 2010 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Pharmacology, Toxicology and Pharmaceutics (4)
Up to Life Sciences44 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2009. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2007–2009, the window the 2010 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2007–2009 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2001 to 2010. | Compare |
|---|---|---|---|---|---|---|---|
1Current Drug MetabolismBentham Science Publishers · Netherlands | 2.59Q1 | 4.95 0.01 down from 2009 | 240 | 13% | — | ||
2Expert Opinion on Drug DeliveryTaylor & Francis · United Kingdom | 2.37Q1 | 5.05 0.98 up from 2009 | 250 | 19% | — | ||
3Pharmaceutical ResearchSpringer Science+Business Media · United States | 2.31Q1 | 5.05 0.53 up from 2009 | 802 | 33% | $4,690 | ||
4European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 2.26Q1 | 4.08 0.91 up from 2009 | 732 | 8% | $4,210 | ||
5Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 2.17Q1 | 4.04 0.38 down from 2009 | 38 | 0% | — | ||
6The Pharmacogenomics JournalSpringer Nature · United Kingdom | 2.16Q1 | 4.32 0.51 down from 2009 | 143 | 40% | $4,890 | ||
7Pharmacogenetics and GenomicsLippincott Williams & Wilkins · United Kingdom | 2.12Q1 | 4.66 0.28 down from 2009 | 356 | 44% | — | ||
8Expert Opinion on Drug Metabolism & ToxicologyTaylor & Francis · United Kingdom | 1.95Q1 | 4.07 0.28 up from 2009 | 346 | 18% | — | ||
9Drug Metabolism and DispositionAmerican Society for Pharmacology and Experimental Therapeutics · United States | 1.88Q1 | 3.83 0.31 down from 2009 | 916 | 26% | $3,500 | ||
10International Journal of PharmaceuticsElsevier BV · Netherlands | 1.79Q1 | 3.55 0.47 up from 2009 | 1,698 | 11% | $4,650 | ||
11PharmacogenomicsFuture Medicine · United Kingdom | 1.68Q1 | 3.69 0.06 up from 2009 | 543 | 18% | — | ||
12Expert Opinion on Drug SafetyTaylor & Francis · United Kingdom | 1.53Q2 | 3.21 0.18 up from 2009 | 222 | 2% | — | ||
13European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.52Q2 | 3.12 1.03 up from 2009 | 531 | 13% | $3,070 | ||
14Drug Metabolism and PharmacokineticsElsevier BV · Japan | 1.44Q2 | 3.07 0.20 up from 2009 | 190 | 8% | $3,580 | ||
15Journal of Pharmaceutical InnovationSpringer Science+Business Media · United Kingdom | 1.42Q2 | 1.98 1.10 up from 2009 | 64 | 10% | $3,990 | ||
16Drug SafetyAdis, Springer Healthcare · New Zealand | 1.40Q2 | 2.78 0.63 up from 2009 | 571 | 7% | $4,990 | ||
17XenobioticaTaylor & Francis · United Kingdom | 1.40Q2 | 2.62 1.23 down from 2009 | 296 | 9% | — | ||
18Current Drug DeliveryBentham Science Publishers · Netherlands | 1.35Q2 | 1.91 0.85 down from 2009 | 122 | 7% | — | ||
19Journal of Analytical ToxicologyOxford University Press · United Kingdom | 1.25Q2 | 2.04 1.06 down from 2009 | 317 | 29% | $4,823 | ||
20Recent Patents on Drug Delivery & FormulationBentham Science Publishers · Netherlands | 1.16Q2 | 1.74 0.21 up from 2009 | 79 | 0% | — | ||
21AAPS PharmSciTechSpringer Science+Business Media · United States | 1.12Q2 | 1.55 0.12 down from 2009 | 464 | 100% | $4,190 | ||
22Drug metabolism and drug interactionsDe Gruyter · Germany | 1.02Q2 | 1.81 0.48 down from 2009 | 49 | 0% | — | ||
23Journal of Fluorine ChemistryElsevier BV · Netherlands | 0.88Q3 | 1.65 0.02 up from 2009 | 612 | 9% | $3,660 | ||
24Assay and Drug Development TechnologiesMary Ann Liebert, Inc. · United States | 0.83Q3 | 1.75 0.29 down from 2009 | 211 | 38% | — | ||
25Biopharmaceutics & Drug DispositionWiley · United Kingdom | 0.81Q3 | 1.70 0.19 up from 2009 | 162 | 19% | $3,800 | ||
26Drug Testing and AnalysisWiley · United States | 0.81Q3 | 1.90 1.90 up from 2009 | 78 | 7% | $4,440 | ||
27Journal of MicroencapsulationTaylor & Francis · United Kingdom | 0.80Q3 | 1.47 0.08 up from 2009 | 246 | 2% | — | ||
28Drug DeliveryOATaylor & Francis · United Kingdom | 0.77Q3 | 1.48 0.16 down from 2009 | 189 | 100% | $2,864 | ||
29Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.73Q3 | 1.51 0.43 up from 2009 | 529 | 2% | — | ||
30Clinical and Translational ScienceOAWiley · United Kingdom | 0.69Q3 | 1.44 0.11 up from 2009 | 135 | 94% | $3,630 | ||
31Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.60Q3 | 0.87 0.22 down from 2009 | 268 | 6% | — | ||
32Drug Metabolism LettersBentham Science Publishers · Netherlands | 0.57Q3 | 1.20 0.42 up from 2009 | 128 | 11% | — | ||
33Current Chemical BiologyBentham Science Publishers · Netherlands | 0.57Q3 | 1.27 0.11 up from 2009 | 150 | 7% | — | ||
34Recent Patents on NanotechnologyBentham Science Publishers · Netherlands | 0.50Q4 | 0.89 0.28 up from 2009 | 73 | 4% | — | ||
35Forensic ToxicologySpringer Science+Business Media · Japan | 0.49Q4 | 1.65 0.43 up from 2009 | 68 | 10% | $2,990 | ||
36Dissolution TechnologiesUnited States | 0.48Q4 | 0.79 0.30 up from 2009 | 81 | 85% | — | ||
37Journal of Drug Delivery Science and TechnologyElsevier BV · France | 0.35Q4 | 0.67 0.07 up from 2009 | 183 | 11% | $3,810 | ||
38YAKUGAKU ZASSHIOAPharmaceutical Society of Japan · Japan | 0.34Q4 | 0.72 0.06 up from 2009 | 679 | 100% | — | ||
39Current Drug TherapyBentham Science Publishers · Netherlands | 0.32Q4 | 0.74 0.01 up from 2009 | 66 | 4% | — | ||
39European Journal of Drug Metabolism and PharmacokineticsAdis, Springer Healthcare · France | 0.32Q4 | 0.46 0.17 down from 2009 | 107 | 5% | $2,690 | ||
41Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.22Q4 | 0.39 0.02 down from 2009 | 223 | 100% | $1,207 | ||
42Annales de Toxicologie AnalytiqueElsevier BV · France | 0.21Q4 | 0.48 0.16 up from 2009 | 94 | 100% | $3,140 | ||
43Brazilian Journal of Pharmaceutical SciencesOAUniversity of São Paulo · Brazil | 0.17Q4 | 0.20no 2009 value | 117 | 100% | — | ||
| 0.05Q4 | 0.07 0.05 up from 2009 | 85 | 100% | — |
Subfields of Pharmacology, Toxicology and Pharmaceutics, compared.
Journals
Citations made in 2010. Corpus-wide, 73.2% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
21 additional Pharmacology, Toxicology and Pharmaceutics journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2007–2009, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2010. Publication window: 2007–2009. How these summaries are calculated
- Ranked journals
- 44
- Window papers (baseline)
- 45,814 +31.7% from indicator year 2007
- Median OJR
- 0.949 -14.3% from indicator year 2007
- Rising journals (2025)
- 4Comparison-group list (4)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2007–2009 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 23 | 27 | 30 | 32 | 32 | 34 | 37 | 38 | 40 | 43 | 44 | 49 | 54 | 61 | 69 | 71 | 74 | 71 | 73 | 75 | 70 | 72 | 75 | 73 | 72 | 68 | |
| Window papers (baseline) | 20,428 | 21,714 | 23,158 | 25,397 | 26,889 | 29,157 | 31,606 | 34,777 | 38,146 | 41,640 | 45,814 | 49,553 | 53,613 | 56,245 | 59,173 | 59,681 | 59,061 | 56,321 | 53,536 | 51,719 | 51,606 | 54,267 | 56,608 | 57,539 | 56,944 | 58,541 | |
| Median OJR | 0.620 | 0.717 | 0.722 | 0.88 | 0.86 | 0.83 | 0.91 | 1.11 | 0.9471 | 0.97 | 0.949 | 1.03 | 0.9469 | 0.80 | 0.70 | 0.720 | 0.61 | 0.7184 | 0.74 | 0.628 | 0.77 | 0.621 | 0.67 | 0.630 | 0.625 | 0.7176 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 2.7% | 62 journals |
| Retracted papers per 1,000 | Pooled rate: 1.221 per 1,000 | 51 journals |
| Output growth | Median: -1.6% | 60 journals |
| Open access share | Median: 44.5% | 68 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,605 | 32 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 22.2% | 67 journals |
| Review share | Median: 0.4% | 68 journals |
| Articles-only OJR | Median: 0.74 | 68 journals |
| Uncited share | Median: 25.2% | 68 journals |
| Citation concentration | Median: 43.7% | 68 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.